Literature DB >> 15236016

The cardiovascular effects of atracurium and it's metabolite.

K Fukushima1, T Aoki, K Watanabe, T Satoh, H Nagashima.   

Abstract

The administration of atracurium to humans has been reported to produce little cardiovascular effects in clinical doses. The cardiovascular effect, histamine-releasing and catecholamine releasing effects of intravenous injection of atracurium 0.6 and 1.2 mg.kg(-1) were studied in man, and also the cardiovascular and catecholamine releasing effects of laudanosine which is a metabolite of atracurium by Hofmann degeneration, were studied in dogs. The increase in human plasma concentration of histamine, hypotension and tachycardia were found with the dose of atracurium 1.2 mg.kg(-1). The intravenous administration of laudanosine 10 micro g.kg(-1) to dogs produced minimal epinephrine, norepinephrine releases and cardiovascular changes.

Entities:  

Year:  1990        PMID： 15236016     DOI： 10.1007/s0054000040045

Source DB:  PubMed          Journal:  J Anesth        ISSN： 0913-8668            Impact factor:   2.078


  7 in total

1.  Histamine-releasing potencies of atracurium, dimethyl tubocurarine and tubocurarine.

Authors:  S J Basta; J J Savarese; H H Ali; J Moss; M Gionfriddo
Journal:  Br J Anaesth       Date:  1983       Impact factor: 9.166

2.  The demonstration of histamine release in clinical conditions: a review of past and present assay procedures.

Authors:  M A Beaven; A Robinson-White; N B Roderick; G L Kauffman
Journal:  Klin Wochenschr       Date:  1982-09-01

3.  Evaluation of atracurium in anaesthetized man.

Authors:  J P Payne; R Hughes
Journal:  Br J Anaesth       Date:  1981-01       Impact factor: 9.166

4.  The pharmacology of atracurium: a new competitive neuromuscular blocking agent.

Authors:  R Hughes; D J Chapple
Journal:  Br J Anaesth       Date:  1981-01       Impact factor: 9.166

5.  Direct evidence that pancuronium and gallamine enhance the release of norepinephrine from the atrial sympathetic nerve by inhibiting prejunctional muscarinic receptors.

Authors:  O Kobayashi; H Nagashima; D Duncalf; I A Chaudhry; L G Harsing; F F Foldes; P L Goldiner; E S Vizi
Journal:  J Auton Nerv Syst       Date:  1987-01

6.  Effect of atracurium and laudanosine on the release of 3H-noradrenaline.

Authors:  M Kinjo; H Nagashima; E S Vizi
Journal:  Br J Anaesth       Date:  1989-06       Impact factor: 9.166

7.  Pharmacology of laudanosine in dogs.

Authors:  P J Hennis; M R Fahey; P C Canfell; W Z Shi; R D Miller
Journal:  Anesthesiology       Date:  1986-07       Impact factor: 7.892
  7 in total
  1 in total

1.  The Incidence of hypotension with continuous infusion atracurium compared to cisatracurium in the Intensive Care Unit.

Authors:  Luke A VanderWeide; Mahmoud Abdel-Rasoul; Anthony Thomas Gerlach
Journal:  Int J Crit Illn Inj Sci       Date:  2017 Apr-Jun
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.